Market Closed -
London S.E.
11:35:20 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
218
GBX
|
+2.59%
|
|
+5.57%
|
+12.26%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
619.4
|
1,211
|
1,563
|
1,137
|
897.9
|
733.7
|
733.7
|
-
|
Enterprise Value (EV)
1 |
378.4
|
1,085
|
1,234
|
723.2
|
563.2
|
672
|
378.6
|
374.1
|
P/E ratio
|
-13.7
x
|
2.95
x
|
273
x
|
-18.8
x
|
-17.9
x
|
-10.3
x
|
-3.66
x
|
-3.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
29.9
x
|
123
x
|
133
x
|
65.4
x
|
57.5
x
|
202
x
|
12.5
x
|
20
x
|
EV / Revenue
|
18.2
x
|
111
x
|
105
x
|
41.6
x
|
36.1
x
|
202
x
|
6.43
x
|
10.2
x
|
EV / EBITDA
|
-3.73
x
|
-8.44
x
|
-10.9
x
|
-5.06
x
|
-2.98
x
|
-4.76
x
|
-1.99
x
|
-1.82
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-3.03
x
|
-2.3
x
|
-1.93
x
|
-1.89
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-33%
|
-43.4%
|
-51.8%
|
-52.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
282,464
|
285,343
|
285,830
|
287,797
|
278,566
|
270,209
|
270,209
|
-
|
Reference price
2 |
2.193
|
4.243
|
5.470
|
3.950
|
3.223
|
2.715
|
2.715
|
2.715
|
Announcement Date
|
4/24/19
|
4/9/20
|
4/15/21
|
4/26/22
|
4/28/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
20.75
|
9.807
|
11.77
|
17.39
|
15.62
|
3.33
|
58.9
|
36.75
|
EBITDA
1 |
-101.5
|
-128.6
|
-112.9
|
-143
|
-188.9
|
-141.3
|
-190
|
-206
|
EBIT
1 |
-
|
-135.4
|
-119.5
|
-150.3
|
-197.8
|
-146.2
|
-212.4
|
-228.7
|
Operating Margin
|
-
|
-1,380.64%
|
-1,015.73%
|
-864.29%
|
-1,266.53%
|
-4,390.36%
|
-360.61%
|
-622.31%
|
Earnings before Tax (EBT)
1 |
-68.44
|
478.5
|
18.97
|
-58.95
|
-92.78
|
-36.1
|
-213
|
-229
|
Net income
1 |
-
|
421.1
|
5.985
|
-60.56
|
-50.35
|
-65.7
|
-144.7
|
-191
|
Net margin
|
-
|
4,294.32%
|
50.86%
|
-348.27%
|
-322.41%
|
-1,972.88%
|
-245.67%
|
-519.86%
|
EPS
2 |
-0.1600
|
1.440
|
0.0200
|
-0.2100
|
-0.1800
|
-0.2400
|
-0.7410
|
-0.7980
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-186
|
-195.6
|
-196.1
|
-197.9
|
FCF margin
|
-
|
-
|
-
|
-
|
-1,190.73%
|
-4,252.17%
|
-332.94%
|
-538.5%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/24/19
|
4/9/20
|
4/15/21
|
4/26/22
|
4/28/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2019 S1
|
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
4.387
|
5.42
|
6.844
|
4.924
|
5.836
|
11.55
|
7.03
|
8.588
|
3.15
|
0.18
|
7.5
|
110.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-70.32
|
-65.08
|
-52.3
|
-66.75
|
-68.08
|
-82.2
|
-101.2
|
-
|
-76.16
|
-
|
-
|
-
|
Operating Margin
|
-1,602.85%
|
-1,200.77%
|
-764.17%
|
-1,355.58%
|
-1,166.55%
|
-711.58%
|
-1,439.43%
|
-
|
-2,417.87%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
11.12
|
467.4
|
174.5
|
-155.5
|
-94.93
|
35.98
|
-55.96
|
-
|
-13.74
|
-
|
-
|
-
|
Net income
1 |
28.34
|
392.8
|
124
|
-118
|
-75.4
|
14.84
|
-28.34
|
-22.01
|
-25
|
-40.69
|
-83.5
|
7
|
Net margin
|
646.05%
|
7,247.27%
|
1,811.18%
|
-2,395.86%
|
-1,291.9%
|
128.44%
|
-403.19%
|
-256.29%
|
-793.78%
|
-22,607.22%
|
-1,113.33%
|
6.35%
|
EPS
|
0.1000
|
-
|
0.4200
|
-0.4000
|
-
|
-
|
-0.1000
|
-
|
-0.0900
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/27/19
|
4/9/20
|
8/27/20
|
4/15/21
|
8/24/21
|
4/26/22
|
8/25/22
|
4/28/23
|
8/29/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
241
|
125
|
329
|
414
|
335
|
283
|
355
|
360
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-186
|
-196
|
-196
|
-198
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-49.6%
|
-62.6%
|
-98.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-0.2700
|
-0.3400
|
-0.4500
|
-0.5500
|
-0.6300
|
-0.6600
|
-0.6600
|
-0.6600
|
Capex
1 |
4.37
|
12.1
|
5.17
|
-
|
7.18
|
7.1
|
7.1
|
7.2
|
Capex / Sales
|
21.04%
|
123.77%
|
43.93%
|
-
|
45.95%
|
154.35%
|
12.05%
|
19.59%
|
Announcement Date
|
4/24/19
|
4/9/20
|
4/15/21
|
4/26/22
|
4/28/23
|
4/25/24
|
-
|
-
|
Last Close Price
2.715
USD Average target price
6.205
USD Spread / Average Target +128.53% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.26% | 734M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|